Conversely to insulin and other oral anti-T2D, the risk of hypoglycemia was also low and comparable between GLP-1R agonists and DPP-IV inhibitors (47), thereby constituting an additional advantage for their possible application in AD treatment, as further discussed in the next section. The gene discussed is INS; the disease is Hypoglycemia.